Myriad Genetics Inc MYGN
$3.03
-4.42%
at last close
Analyst Consensus
- Consensus Rating
- Hold (1 Buy · 3 Hold · 0 Sell)
- Average Price Target
- $5.38
- Implied Upside
- +77.4%
- Price Target Range
- $3.00 – $8.50
- Analysts (12 mo)
- 4
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-03 | Wells FargoEvan Stampler |
Maintains | Equal-weight | $6 → $3 |
| 2026-07-31 | TD CowenKyle Boucher |
Maintains | Hold | $6 → $4 |
| 2026-05-06 | TD CowenKyle Boucher |
Maintains | Hold | $7 → $6 |
| 2026-05-06 | Wells FargoBrandon Couillard |
Maintains | Equal-weight | $6 → $6 |
| 2026-02-24 | UBSLu Li |
Maintains | Neutral | $8 → $6 |
| 2026-02-24 | Wells FargoBrandon Couillard |
Maintains | Equal-weight | $7 → $6 |
| 2025-11-11 | Piper SandlerDave Weiner |
Maintains | Overweight | $9 → $9 |
| 2025-11-05 | Wells FargoBrandon Couillard |
Maintains | Equal-weight | $6 → $7 |
| 2025-11-04 | TD CowenDan Brennan |
Maintains | Hold | $8 → $9 |
| 2025-11-04 | UBSLu Li |
Maintains | Neutral | $6 → $8 |
| 2025-05-21 | ScotiabankSung Ji Nam |
Downgrades | Sector outperform → Sector perform | $20 → $6 |
| 2025-05-15 | Piper SandlerDave Weiner |
Maintains | Overweight | $13 → $9 |
| 2025-05-08 | Wells FargoBrandon Couillard |
Downgrades | Overweight → Equal-weight | $22 → $6 |
| 2025-05-07 | Goldman SachsMatthew Sykes |
Maintains | Buy | $14 → $8 |
| 2025-05-07 | UBSLu Li |
Maintains | Neutral | $16 → $7 |
| 2025-05-07 | Raymond JamesAndrew Cooper |
Reiterates | Outperform | $19 → $10 |
| 2025-04-17 | Goldman SachsMatthew Sykes |
Maintains | Buy | $18 → $14 |
| 2025-04-09 | GuggenheimSubbu Nambi |
Downgrades | Buy → Neutral | — |
| 2025-04-01 | ScotiabankSung Ji Nam |
Maintains | Sector outperform | $24 → $20 |
| 2025-03-12 | Piper SandlerDave Weiner |
Upgrades | Neutral → Overweight | $12 → $13 |
| 2025-03-04 | Piper SandlerDave Weiner |
Maintains | Neutral | $14 → $12 |
| 2025-03-03 | B of A SecuritiesDerik De Bruin |
Maintains | Underperform | $13 → $11 |
| 2025-02-25 | Raymond JamesAndrew Cooper |
Reiterates | Outperform | $27 → $19 |
| 2025-02-25 | UBSLu Li |
Maintains | Neutral | $18 → $16 |
| 2025-02-12 | Craig-HallumJohn Wilkin |
Initiates coverage on | Buy | $29 |
| 2025-01-30 | Piper SandlerJohn Peterson |
Maintains | Neutral | $24 → $14 |
| 2025-01-28 | Goldman SachsMatthew Sykes |
Maintains | Buy | $29 → $18 |
| 2025-01-16 | Stephens & Co.Mason Carrico |
Reiterates | Equal-weight | $20 |
| 2024-12-13 | B of A SecuritiesDerik De Bruin |
Maintains | Underperform | $15 → $13 |
| 2024-12-10 | UBSLu Li |
Initiates coverage on | Neutral | $18 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.03
- Market Cap
- $289.82 million
- 52-Week Range
- $2.74 – $8.59
- Average Volume
- 2.02 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.